An imiquimod (IMQ)-induced psoriasis-like mouse model was employed to assess the therapeutic effects of orally administered clove extract and eugenol. iTRAQ-based LC–MS/MS proteomics were performed to identify molecular alterations, followed by bioinformatics analyses.
